GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SIGA Technologies Inc (NAS:SIGA) » Definitions » Net-Net Working Capital

SIGA Technologies (SIGA Technologies) Net-Net Working Capital : $1.98 (As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is SIGA Technologies Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

SIGA Technologies's Net-Net Working Capital for the quarter that ended in Dec. 2023 was $1.98.

The industry rank for SIGA Technologies's Net-Net Working Capital or its related term are showing as below:

SIGA's Price-to-Net-Net-Working-Capital is ranked better than
68.25% of 422 companies
in the Drug Manufacturers industry
Industry Median: 7.78 vs SIGA: 4.44

SIGA Technologies Net-Net Working Capital Historical Data

The historical data trend for SIGA Technologies's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SIGA Technologies Net-Net Working Capital Chart

SIGA Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.34 1.43 1.84 1.76 1.98

SIGA Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.76 1.74 1.18 1.06 1.98

Competitive Comparison of SIGA Technologies's Net-Net Working Capital

For the Drug Manufacturers - Specialty & Generic subindustry, SIGA Technologies's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SIGA Technologies's Price-to-Net-Net-Working-Capital Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SIGA Technologies's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where SIGA Technologies's Price-to-Net-Net-Working-Capital falls into.



SIGA Technologies Net-Net Working Capital Calculation

SIGA Technologies's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net-Net Working Capital(A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(150.146+0.75 * 21.131+0.5 * 64.218-57.494
-0-0)/71.0916
=1.98

SIGA Technologies's Net-Net Working Capital (NNWC) per share for the quarter that ended in Dec. 2023 is calculated as

Net-Net Working Capital(Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(150.146+0.75 * 21.131+0.5 * 64.218-57.494
-0-0)/71.0916
=1.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


SIGA Technologies  (NAS:SIGA) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


SIGA Technologies Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of SIGA Technologies's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


SIGA Technologies (SIGA Technologies) Business Description

Traded in Other Exchanges
N/A
Address
31 East 62nd Street, New York, NY, USA, 10065
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus.
Executives
Evan A. Knisely director C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Jay Varma director C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Ford Harold Eugene Jr. director 4921 WILLIAM ARNOLD ROAD, MEMPHIS TN 38117
James Antal director 30952 STEEPLECHASE DRIVE, SAN JUAN CAPISTRANO CA 92675
Holly L. Phillips director C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Gary J. Nabel director C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Julian Nemirovsky director 35 EAST 62ND STREET, NEW YORK NY 10065
Edward P. Taibi director 35 EAST 62ND STREET, NEW YORK NY 10065
Jaymie A Durnan director C/O SIGA TECHNOLOGIES, INC.,, 31 EAST 62ND STREET, NEW YORK NY 10065
Gomez Phillip Louis Iii officer: Chief Executive Officer 7220 VAN NESS COURT, MCLEAN VA 22101
Daniel J Luckshire officer: Executive VP & CFO C/O SIGA TECHNOLOGIES, INC., 35 EAST 62ND STREET, NEW YORK NY 10065
Paul G Savas director 35 EAST 62ND STREET, NEW YORK NY 10021
Julie Kane director 77 BEALE ST, P.O. BOX 770000, SAN FRANCISCO CA 94177
Dennis E Hruby officer: Chief Scientific Officer SIGA TECHNOLOGIES, INC., 420 LEXINGTON AVENUE, SUITE 601, NEW YORK NY 10170
Michael J Bayer director 1100 N GLEBE ROAD, ARLINGTON VA 22201

SIGA Technologies (SIGA Technologies) Headlines

From GuruFocus

SIGA Technologies Receives Approval from UK for Tecovirimat

By GuruFocusNews GuruFocusNews 07-08-2022

SIGA Declares Special Cash Dividend of $0.45 Per Share

By sperokesalga sperokesalga 05-04-2023

SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX � (tecovirimat) for Treatment of Monkeypox

By deactivated_deactivated_Ds*** deactivated_deactivated_Ds*** 10-12-2022